Coronavirus Drug: Cipla gets DCGI nod to sell Favipiravir under brand 'Ciplenza'
Drug maker Cipla Ltd. on Friday said it has received regulatory approval from Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza to treat mild to moderate Covid-19 patients.
Favipiravir is an off patent, oral antiviral drug that has been shown to hasten clinical recovery in Covid-19 patients with mild to moderate symptoms. Photo: Reuters